Showing 81-90 of 3058 results for "".
Promising Results for Investigational Antisense Oligonucleotide Treatment for Dravet Syndrome
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/promising-results-for-investigational-antisense-oligonucleotide-treatment-for-dravet-syndrome-1/35435/Joseph Sullivan, MD, Professor, UCSF School of Medicine, San Francisco, CA, describes encouraging results from the SWALLOWTAIL and LONGWING studies of an investigational treatment for individuals with Dravet syndrome, including outcomes related to seizure frequency, cognition, and behavior.Emerging Use of Ketamine for the Treatment of Migraine and Other Headache Disorders
https://practicalneurology.com/programs/practical-neurology/emerging-use-of-ketamine-for-the-treatment-of-migraine-and-other-headache-disorders/35431/Peter McAllister, MD, FAAN, Chief Medical Officer of the New England Institute for Neurology and Headache, Stamford, CT, discusses the application of ketamine in neurologic practice for the treatment of migraine and other headache disorders, including experiences from his clinical practice.The Evolving Therapeutic Landscape for Parkinson Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/the-evolving-therapeutic-landscape-for-parkinson-disease/36164/Mark Stacy, MD, William E. Murray Professor of Neurology, Medical University of South Carolina, Charleston, SC, discusses the evolving therapeutic landscape for Parkinson disease, highlighting promising advances in neuroprotective therapies, biomarkers, personalized medicine, and innovative clinicalModern Glioma Management: Integrating Molecular Markers and New Targeted Therapies
https://practicalneurology.com/diseases-diagnoses/neuro-oncology/modern-glioma-management-integrating-molecular-markers-and-new-targeted-therapies/48967/Patrick Y. Wen, MD, Dana-Farber Cancer Institute, Boston, MA, discusses current standards of care for low- and high-grade gliomas, including the importance of comprehensive molecular testing, the World Health Organization classification of tumors of the central nervous system, and newly available thBiomarker Testing Modalities for Alzheimer Disease
https://practicalneurology.com/videos/neurology-in-motion/biomarker-testing-modalities-for-alzheimer-disease/35432/Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses key factors physicians should consider when ordering a biomarker test and recommendations for how physicians should communicate the need for a particular test with their pAdvances in ALS: New Targets, Trials, and Care Strategies
https://practicalneurology.com/diseases-diagnoses/neuromuscular/advances-in-als/37125/Merit Cudkowicz, MD, Julieanne Professor of Neurology, Harvard Medical School, Boston, MA, discusses the evolving landscape of treatment for ALS, including FDA-approved disease-modifying therapies, the importance of genetic testing, the emergence of gene therapies, and the promising clinical trial pKey Highlights from POLARIS Gene Therapy Trial Data for Dravet Syndrome
https://reachmd.com/programs/practical-neurology/key-highlights-from-polaris-gene-therapy-trial-data-for-dravet-syndrome/39916/Joseph Sullivan, MD, University of California, San Francisco, CA, reviews early POLARIS gene therapy trial data in Dravet syndrome, highlighting favorable safety, dose-dependent seizure reduction, and emerging improvements in communication and cognitive development compared with natural history.Study Reveals Link Between Depression, Epilepsy, and Treatment Failure
https://practicalneurology.com/programs/practical-neurology/study-reveals-link-between-depression-epilepsy-and-treatment-failure/39907/Samuel W. Terman, MD, University of Michigan, Ann Arbor, MI, provides details about a new study based on claims data showing how depression affects treatment patterns and failure rates among adults newly diagnosed with epilepsy.Vagus Nerve Stimulation Reduced Rescue Medication Use and Decreased Family Burden
https://practicalneurology.com/programs/practical-neurology/vagus-nerve-stimulation-reduced-rescue-medication-use-and-decreased-family-burden/39913/James Wheless, MD, University of Tennessee Medical Center, Memphis, TN, reports on data demonstrating that using vagus nerve stimulation in patients with drug-resistant epilepsy can reduce rescue medication use, emergency department visits, and hospitalizations while improving patient and family quaPhysicians with Substance Use Disorder, Part I: Overview and A Personal Journey Through Recovery
https://practicalneurology.com/columns/practice-management/physicians-with-substance-use-disorder-part-1-overview-and-a-personal-journey-through-recovery/30090/Chris Bundy, MD, Executive Medical Director, Washington Physicians Health Program, provides an overview of physician substance use disorder, including prevalence, risk factors, and impediments to recovery as well as details about his own journey with recovery.